Protara Therapeutics
TARA
81 hedge funds and large institutions have $114M invested in Protara Therapeutics in 2025 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 26 reducing their positions, and 8 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
27% more capital invested
Capital invested by funds: $90.1M → $114M (+$23.9M)
7% more funds holding
Funds holding: 76 → 81 (+5)
8% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 26
9.07% less ownership
Funds ownership: 77.02% → 67.95% (-9.1%)
30% less call options, than puts
Call options by funds: $183K | Put options by funds: $261K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$1.44M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$995K |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$589K |
| 4 |
Renaissance Technologies
New York
|
+$535K |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$417K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$3.15M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.59M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$2.58M |
| 4 |
SC
Stempoint Capital
New York
|
-$2.53M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.21M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SS
76
SBI Securities
Tokyo,
Japan
| $457 | +$6 | +2 | +2% |
|
77
Fidelity Investments
Boston,
Massachusetts
| $405 | +$301 | +93 | New |
|
78
Osaic Holdings
Scottsdale,
Arizona
| $312 | – | – | – |
|
|
FFA
79
Farther Finance Advisors
San Francisco,
California
| $239 | +$178 | +55 | New |
|
|
AAP
80
Arax Advisory Partners
Denver,
Colorado
| $209 | +$155 | +48 | New |
|
|
RCM
81
RA Capital Management
Boston,
Massachusetts
| – | -$3.15M | -1,039,295 | Closed |
|
|
OM
82
Opaleye Management
Boston,
Massachusetts
| – | -$2.59M | -855,000 | Closed |
|
|
WP
83
Woodline Partners
San Francisco,
California
| – | -$2.58M | -851,674 | Closed |
|
|
84
Adage Capital Partners
Boston,
Massachusetts
| – | -$1.21M | -400,000 | Closed |
|
85
Walleye Capital
New York
| – | -$488K | -161,091 | Closed |
|
86
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$103K | -33,982 | Closed |
|
|
CSS
87
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$59.6K | -19,679 | Closed |
|
88
Raymond James Financial
St Petersburg,
Florida
| – | -$821 | -271 | Closed |
|
89
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$136 | +42 | New |
|
TARA Hedge Fund Activity: Q3 2025 in Review
81 of the 7,626 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q3 2025, worth a combined $114M — up 27% from $90.1M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new TARA positions and 8 closed out — a net gain of 6 holders — while 24 added to existing stakes and 26 trimmed.
The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $1.44M. The largest seller was RA Capital Management, exiting entirely with an estimated $3.15M sold.
- 81 institutional investors held Protara Therapeutics (TARA) as of Q3 2025, up from 76 in Q2 2025.
- Funds reported $114M of Protara Therapeutics stock for Q3 2025, up 27% quarter-over-quarter.
- 14 funds opened new Protara Therapeutics positions in Q3 2025 and 8 closed out, a net change of +6 holders.
- The largest Protara Therapeutics buyer in Q3 2025 was Driehaus Capital Management, an estimated $1.44M added.
- The largest Protara Therapeutics seller in Q3 2025 was RA Capital Management, an estimated $3.15M sold.
Based on aggregated 13F filings for Q3 2025.